Imatinib: Cost-effective in the treatment of gastrointestinal stromal tumors

被引：0
|
作者：
Finketstein, Stan N. [1 ]
Huse, Daniel M. [2 ]
Glendenning, G. A. [3 ]
Blanke, Charles D. [4 ,5 ]
Joensuu, Heikki [6 ]
von Mehren, Margaret [7 ]
Demetri, George D. [8 ]
机构：
[1] Harvard Mit Div Hlth Sci & Technol, MIT Sloan Sch Management, Cambridge, MA USA
[2] Thomson Medstat, Market Scan Studies, Cambridge, MA USA
[3] Novartis Pharmaceut, Florham Pk, NJ USA
[4] Oregon Hlth & Sci Univ, Portland, OR 97201 USA
[5] Portland Vet Med Ctr, Dept Oncol, Portland, OR USA
[6] Univ Helsinki, Dept Oncol, Helsinki, Finland
[7] Fox Chase Canc Ctr, Dept Oncol, Philadelphia, PA 19111 USA
[8] Dana Farber Canc Inst, Ctr Sarcoma & Bone Oncol, Boston, MA 02115 USA
来源：
ANNALS OF ONCOLOGY | 2004年 / 15卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：201 / 201
页数：1
相关论文
共 50 条
  • [31] Cost Effectiveness of Imatinib Mesylate in the Treatment of Advanced Gastrointestinal Stromal Tumours
    Daniel M. Huse
    Margaret von Mehren
    Gregory Lenhart
    Heikki Joensuu
    Charles Blanke
    Weiwei Feng
    Stan Finkelstein
    George Demetri
    Clinical Drug Investigation, 2007, 27 : 85 - 93
  • [32] Cost effectiveness of imatinib mesylate in the treatment of advanced gastrointestinal stromal tumours
    Huse, Daniel M.
    von Mehren, Margaret
    Lenhart, Gregory
    Joensuu, Heikki
    Blanke, Charles
    Feng, Weiwei
    Finkelstein, Stan
    Demetri, George
    CLINICAL DRUG INVESTIGATION, 2007, 27 (02) : 85 - 93
  • [33] Cost-effectiveness of three years of adjuvant imatinib in gastrointestinal stromal tumors (GIST).
    Sanon, Myrlene
    Parthan, Anju
    Taylor, Douglas
    Coombs, John
    Paolantonio, Marc
    Sasane, Medha
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [34] Assessment of gastrointestinal stromal tumors with computed tomography following treatment with imatinib mesylate
    Sith Phongkitkarun
    Cholada Phaisanphrukkun
    Janjira Jatchavala
    Ekaphop Sirachainan
    World Journal of Gastroenterology, 2008, (06) : 892 - 898
  • [35] Imatinib Mesylate: Past Successes and Future Challenges in the Treatment of Gastrointestinal Stromal Tumors
    Ksienski, Doran
    CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2011, 5 : 365 - 379
  • [36] Assessment of gastrointestinal stromal tumors with computed tomography following treatment with imatinib mesylate
    Phongkitkarun, Sith
    Phaisanphrukkun, Cholada
    Jatchavala, Janjira
    Sirachainan, Ekaphop
    WORLD JOURNAL OF GASTROENTEROLOGY, 2008, 14 (06) : 892 - 898
  • [37] Treatment of localized anorectal gastrointestinal stromal tumors with preoperative imatinib mesylate therapy
    Wang, W.
    Luo, S.
    Chen, W.
    Kang, L.
    Deng, Y.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S412 - S412
  • [38] Gastrointestinal stromal tumors treatment in the Imatinib era. The role of fair indication
    Vendettuoli, M.
    Pironi, D.
    Pontone, S.
    Panarese, A.
    La Gioia, G.
    Arcieri, S.
    Romani, A. M.
    Palazzini, G.
    Filippini, A.
    MINERVA CHIRURGICA, 2012, 67 (02) : 165 - 173
  • [39] Surgical treatment of gastrointestinal stromal tumors in the imatinib (STI-571) era
    Wu, PC
    Langerman, A
    Ryan, CW
    Hart, J
    Swiger, S
    Posner, MC
    SURGERY, 2003, 134 (04) : 656 - 665
  • [40] Optimized dose of imatinib for treatment of gastrointestinal stromal tumors: A meta-analysis
    Liu, Shang Long
    Chen, Ge
    Zhao, Yu Pei
    Wu, Wen Ming
    Zhang, Tai Ping
    JOURNAL OF DIGESTIVE DISEASES, 2013, 14 (01) : 16 - 21
12345